This research addresses the critical challenge of early detection in pancreatic ductal adenocarcinoma (PDAC) by exploring urinary biomarkers and integrating artificial intelligence (AI) models. The study emphasizes the significance of liquid biopsy, particularly in urine, as a noninvasive approach for real-time monitoring of PDAC. Traditional diagnostic methods face limitations, necessitating the exploration of novel biomarkers and AI applications. The research employs two distinct methodologies: Method 1, utilizing a Bagged Ensemble of decision trees, and Method 2, employing an optimized decision tree model. Comprehensive evaluations, including accuracy, confusion matrices, and ROC curves, reveal the effectiveness of both methods in PDAC diagnostics. The comparison highlights Method 1's marginally superior performance in training, while Method 2 excels in distinguishing between benign and PDAC cases during testing. The research underscores the potential of AI-driven urinary biomarker classification as a robust diagnostic tool for improved outcomes in pancreatic cancer The evaluation results against state-of-the-art models, further emphasize the superiority of the proposed ensemble-based methods.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.compbiomed.2025.109997 | DOI Listing |
Ann Oncol
February 2025
Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. Electronic address:
Background: We predicted the number of cancer deaths and rates for 2025 in the European Union (EU), its five most populous countries, and the UK, focusing on breast cancer.
Materials And Methods: We derived population data and death certificates for all cancers and major sites for the EU, France, Germany, Italy, Poland, Spain, and the UK since 1970, from the World Health Organization and United Nations databases. Estimates for 2025 were computed by linear regression on recent trends identified through Poisson joinpoint regression, considering the slope of the most recent trend segment.
J Genet Eng Biotechnol
March 2025
Karachi Medical and Dental College, Pakistan. Electronic address:
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with a five-year survival rate of just 7%. Its late diagnosis and limited treatment options contribute to poor outcomes. Immunotherapy has had little success due to PDAC's dense and immunosuppressive tumor environment.
View Article and Find Full Text PDFKeio J Med
March 2025
Center for Hereditary Breast and Ovarian Cancer Syndrome, Keio University Hospital, Tokyo, Japan.
Hereditary breast and ovarian cancer syndrome (HBOC) is traditionally associated with mutations in the BRCA1 and BRCA2 genes, predominantly impacting breast, ovarian, pancreatic, and prostate cancers. However, recent research suggests that these mutations may also predispose carriers to a broader spectrum of malignancies, including biliary tract, cervical, colorectal, endometrial, esophageal, and gastric cancers. This review presents findings from extensive datasets, including a significant study from a nationwide Japanese biobank that examined cancer risks in 63,828 patients and 37,086 controls.
View Article and Find Full Text PDFOccup Environ Med
March 2025
Research Directorate, Veterans Affairs Canada, Charlottetown, Prince Edward Island, Canada
Objectives: To describe rates of overall and type-specific primary cancers in Canadian Armed Forces (CAF) personnel and Veterans with a first enrolment in the CAF between 1976 and 2016, with comparisons to the Canadian general population (CGP).
Methods: This retrospective cohort study linked CAF administrative data to national cancer registries. Primary cancer diagnoses were ascertained from 1976 to 2017.
Int J Radiat Oncol Biol Phys
March 2025
Department of Radiation Oncology, Taipei Medical University Hospital, Taipei, Taiwan; National Institute of Cancer Research, National Health Research Institutes, Miaoli, Taiwan; Department of Oncology, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Electronic address:
Background: Randomized trials and meta-analyses have indicated longer survival with neoadjuvant than with adjuvant therapy in patients with resectable or borderline resectable (R/BR) pancreatic adenocarcinoma. Despite the efficacy of chemotherapy, the role of radiotherapy as an adjuvant or neoadjuvant treatment for patients with R/BR pancreatic adenocarcinoma remains unclear. In this systematic review and meta-analysis, we compared the benefits of additional chemoradiotherapy (CRT) to neoadjuvant chemotherapy (NAC) with NAC alone for R/BR pancreatic adenocarcinoma.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!